Antipsychotics and sexual dysfunction: Sexual dysfunction: Part III by Nagaraj, Anil Kumar Mysore et al.
University of Wollongong 
Research Online 
Graduate School of Medicine - Papers (Archive) Faculty of Science, Medicine and Health 
2009 
Antipsychotics and sexual dysfunction: Sexual dysfunction: Part III 
Anil Kumar Mysore Nagaraj 
Mysore Medical College & Research Institute 
nagesh Pai 
University of Wollongong, nagesh@uow.edu.au 
Satheesh Rao 
K S Hegde Medical Academy 
Follow this and additional works at: https://ro.uow.edu.au/medpapers 
 Part of the Medicine and Health Sciences Commons 
Citation 
Nagaraj, Anil Kumar Mysore; Pai, nagesh; and Rao, Satheesh, 2009, Antipsychotics and sexual 
dysfunction: Sexual dysfunction: Part III. 
https://ro.uow.edu.au/medpapers/658 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Antipsychotics and sexual dysfunction: Sexual dysfunction: Part III 
Abstract 
Satisfying sexual experience is an essential part of a healthy and enjoyable life for most people. 
Antipsychotic drugs are among the various factors that affect optimal sexual functioning. Both 
conventional and novel antipsychotics are associated with significant sexual side effects. This review has 
presented various studies comparing different antipsychotic drugs. Dopamine antagonism, increased 
serum prolactin, serotonergic, adrenergic and cholinergic mechanisms are all proposed to be the 
mechanisms for sexual dysfunction. Drug treatment for this has not given satisfactory long-term results. 
Knowledge of the receptor pharmacology of an individual antipsychotic will help to determine whether it 
is more or less likely to cause sexual side effects and its management. 
Disciplines 
Medicine and Health Sciences 
Publication Details 
Nagaraj, A., Pai, N. Brahmavar. & Rao, S. (2009). Antipsychotics and sexual dysfunction: Sexual 
dysfunction: Part III. Online Journal of Health and Allied Sciences, 8 (3), 1-6. 
This journal article is available at Research Online: https://ro.uow.edu.au/medpapers/658 
Review:
Antipsychotics and Sexual Dysfunction :: Sexual Dysfunction: Part III
Anil Kumar Mysore Nagaraj, Senior Resident, Dept of Psychiatry, Mysore Medical College & Research Institute, Mysore - 570001, India,
Nagesh Brahmavar Pai, Clinical Associate Professor, Graduate School of Medicine, University of Wollongong, Australia,
Satheesh Rao, Professor and Head, Dept of Psychiatry, K S Hegde Medical Academy, Mangalore, India
Address For Correspondence:
Anil Kumar Mysore Nagaraj,
Senior Resident, Dept of Psychiatry, Mysore Medical College & Research Institute, Mysore - 570001, India. E-mail: nagarajakm24@gmail.com
Citation: Anil Kumar MN, Pai NB, Rao S. Antipsychotics and Sexual Dysfunction. Online J Health Allied Scs. 2009;8(3):1
URL: http://www.ojhas.org/issue31/2009-3-1.htm
Open Access Archives: http://cogprints.org/view/subjects/OJHAS.html and http://openmed.nic.in/view/subjects/ojhas.html
Submitted: Sep 20, 2009; Accepted: Sep 30, 2009; Published: Nov 15, 2009
Abstract:
Satisfying sexual experience is an essential part of a healthy 
and enjoyable life for most people. Antipsychotic drugs are 
among  the  various  factors  that  affect  optimal  sexual 
functioning. Both conventional and novel antipsychotics are 
associated with  significant  sexual  side effects.  This  review 
has  presented  various  studies  comparing  different 
antipsychotic drugs. Dopamine antagonism, increased serum 
prolactin,  serotonergic,  adrenergic  and  cholinergic 
mechanisms are all proposed to be the mechanisms for sexual 
dysfunction.  Drug  treatment  for  this  has  not  given 
satisfactory  long-term  results.  Knowledge  of  the  receptor 
pharmacology  of  an  individual  antipsychotic  will  help  to 
determine  whether it  is more  or less likely to cause sexual 
side  effects  and  its  management.
Key Words:  Sexual dysfunction, Desire, Erection, Orgasm, 
Ejaculation, Antipsychotics
Introduction:
Sex  is  a  motive  force  bringing  two  people  into  intimate 
contact. Satisfying sexual experience is an essential part of a 
healthy  and  enjoyable  life  for  most  people.  Sexual 
dysfunction can result from a wide variety of psychological 
and  physical  causes  like  age,  opportunity  in  the  living 
condition,  medical  disorders,  psychiatric  disorders, 
medications.  Among  medications  antihypertensives, 
diuretics,  antihistamines,  antidepressants,  benzodiazepines 
and antipsychotics  are  the  common  agents  associated  with 
sexual  dysfunction.(1)  Antipsychotics,  either  typical  or 
atypical  are  commonly  used in  the  acute  and maintenance 
phases of schizophrenia. Literature reveals significant rates of 
sexual  dysfunction  among  both  typical  and  atypical 
antipsychotics  and  this  adverse  effect  is  particularly 
important in many ways. It affects their self-esteem, causes 
trouble for their sexual partners, interferes with their quality 
of life and compromises treatment  compliance.(2-6) Sexual 
dysfunction  appears  to  be  due  to  direct  consequence  of 
dopamine  antagonism.  However  other  mechanisms  like 
elevated serum prolactin level, serotonergic,  adrenergic and 
anticholinergic  mechanisms  are  also  important.(6-8) 
Bromocriptine,  cabergoline,  amantadine,  shakuyaku-kanzo-
to, and sildenafil are some of the drugs tried in antipsychotic 
induced sexual dysfunction. But there is no robust evidence 
that  these  agents  have  proper  efficacy  in  treating  the 
antipsychotic-induced sexual  dysfunction.(9)  Knowledge  of 
the receptor pharmacology of an individual antipsychotic will 
help to determine whether it is more or less likely to cause 
sexual side effects.(10) This review presents various studies 
that have looked into different antipsychotics for sexual side 
effects  and  approved  treatment  options  for  antipsychotic 
associated sexual dysfunction.
Studies  of  sexual  dysfunction  due  to  antipsychotics  in 
schizophrenia:
This  aspect  of  antipsychotics  was  not  extensively  studies 
earlier, for two reasons. One is the low rate of spontaneous 
reporting by the patient and the other being embarrassment 
on the part of the clinician, especially when the patient is of 
opposite  sex.  Antipsychotics  being  the  mainstay  in  the 
treatment  of  schizophrenia,  sexual  dysfunction  due  to 
antipsychotics have been currently studied extensively in this 
patient group.
The landmark study by Kotin and co-workers is one of the 
earliest studies in this area. They studied sexual dysfunction 
among 87 schizophrenic patients. Fiftyseven of them were on 
thioridazine and another 30 were on other antipsychotics like 
chlorpromazine, trifluperazine, fluphenazine, haloperidol and 
thiothixene. Sixty percent of those who were on thioridazine 
reported sexual dysfunction as against 25% of those on other 
antipsychotics.  In  this,  49%  had  ejaculatory  problems 
including  retrograde  ejaculation  and  44%  had  erectile 
problems in the thioridazine group, as against 0% and 19% 
respectively  in  the  other  group.  The  study was  limited  by 
direct  interview  technique,  only  male  patients  and  low 
sample size.(11)
Ghadirian  and  colleagues  studied  sexual  dysfunction  and 
plasma  prolactin  levels  in  55  neuroleptic  treated 
schizophrenic  patients  of  which  26  were  males  and  29 
females.  Most  of  them were  on  fluphenazine.  A  specially 
designed scale was used, though it was not validated. Fifty 
four percent of males and 30% of females reported impaired 
sexual  functioning.  Further,  91%  of  females  reported 
menstrual  problems.  Plasma  prolactin  levels  significantly 
correlated  in  male  sexual  dysfunction  but  not  in  females 
though here it was significantly correlated to their menstrual 
problems. There were no placebo controls.(12)
In the study of sexual function in men with schizophrenia, by 
Burke and his team, 50% reported erectile dysfunction. They 
were  receiving  either  haloperidol  or  fluphenazine. 
Dysfunction  was  significantly  associated  with  greater 
biological evidence of dopamine blockade, by way of severe 
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EPS and high serum prolactin levels.  The sample  size was 
too small (N = 20) and there was no control group. (13)
Another  study  compared  sexual  dysfunction  among  male 
schizophrenics  with  and  without  treatment.  This  was  a 
unique study, first of its kind, in which there were 20 drug 
free  patients,  51  patients  on  neuroleptics  and  51  normal 
controls who were assessed on a questionnaire designed by 
Schiavi  et  al.  (1990).  It  revealed  that  untreated 
schizophrenics had significantly reduced frequency of sexual 
thoughts,  though  erection  and  ejaculation  was  preserved. 
Impairment  in  arousal,  erection  and  orgasm were  reported 
significantly more by the treated patients than the untreated, 
though they also reported reduced desire. However it inferred 
that  neuroleptic  treatment  has  beneficial  effect  on  sexual 
desire.(14)
Kockott  and  Pfeiffer  studied  sexual  disorders  in  mixed 
population  of  non  acute  psychiatric  outpatients  which 
included  100  schizophrenics,  58  patients  of  affective 
psychosis and 30 patients receiving dermatological treatment, 
as control group. Rated on a sexuality questionnaire, 49% of 
schizophrenics,  36.2%  of  those  with  mood  disorder  and 
13.3%  of  controls  had  a  sexual  dysfunction.  The  most 
frequent form of sexual dysfunction experienced in all groups 
was a low desire. 88 out of 100 patients with schizophrenia 
were  on  medication  and  depot  preparations  of  haloperidol 
and  flupenthixol  were  the  medicines  used  by  majority  of 
patients. 60% of haloperidol group and 44% of flupenthixol 
group reported sexual dysfunction. Neither the nature of the 
pharmaceuticals nor the dose level had a specific influence 
on the frequency of sexual dysfunctions. (15)
Smith and co-workers studied sexual dysfunction among 101 
schizophrenic  patients  on  typical  antipsychotics 
(flupenthixol,  fluphenazine,  haloperidol,  zuclopenthixol, 
thioridazine,  trifluoperazine,  pimozide),  57 normal  controls 
and  55  controls  attending  a  sexual  dysfunction  clinic. 
Assessed on a sexual functioning questionnaire designed by 
the  authors,  45%  of  schizophrenic  patients,  17%  normal 
controls and 61% of controls attending the sexual dysfunction 
clinic  reported  sexual  dysfunction.  This  study  has  also 
compared  different  typical  antipsychotics  for  sexual 
dysfunction among both males and females. Impaired libido 
was  most  common  with  aliphatic  phenothiazines  in  males 
where as in  females,  with  substituted  benzamides.  Arousal 
difficulties were most common with substituted benzamides 
and orgasmic/ejaculatory problems with thioxanthines in both 
sexes.  Absence  of  unmedicated  psychiatric  patients  and 
smaller sample to ascertain the effect of specific medications 
limited the study.(2)
Raja and Azzoni studied various aspects of sexual behavior 
including  awareness  of  high  risk  behavior,  sexually 
transmitted  diseases  and  sexual  problems  due  to 
psychotropics among mixed population of psychotic patients. 
They assessed 117 symptomatic  patients  of  both  sexes,  39 
each of  schizophrenia,  schizoaffective  disorder  and bipolar 
disorder, by the modified version of the sexual interest and 
sexual performance questionnaire developed by Azzoni and 
his  team.  The  patients  were  on  different  antipsychotics, 
benzodiazepines and anticholinergic drugs, but the names of 
drugs  are  not  mentioned  in  the  study.  Overall,  38.5%  of 
patients reported detrimental effects of psychoactive drugs on 
their  sexuality.  Impaired  desire  was  the  most  commonly 
reported  sexual  dysfunction.  Patients  with  schizophrenia 
scored  low  on  all  aspects  of  sexuality  compared  to  other 
groups.(16)
The  above  studies  infer  that  all  the  classes  of  typical 
antipsychotics  (Dopamine  receptor  antagonists)  are 
associated  with  significant  sexual  side  effects.  Atypical 
antipsychotics  (Serotonin  Dopamine  antagonists)  became 
popular by the end of last century and were thought to have a 
better  side effect profile.  It  became essential  to study their 
sexual  side  effects  as  that  was  a  significant  factor  for 
medication compliance.
Studies  comparing  sexual  dysfunction due  to typical  & 
atypical antipsychotics:
A  study  by  Hummer  and  his  colleagues  compared  sexual 
dysfunction among schizophrenics on clozapine, an atypical 
antipsychotic  with  those  on  haloperidol,  a  typical 
antipsychotic.  One  hundred  patients  on  clozapine  and  53 
patients on haloperidol  (including males and females) were 
rated  on  UKU  side  effect  rating scale.  Fifty  eight  percent
had reduced  desire,  27%  impaired  arousal  and  22%  orgas-
mic difficulties  in  the  haloperidol  group,  as  compared  to  
50% reduced desire,  24% arousal difficulties and 21% orga-
smic difficulties in the clozapine group.  Thus interestingly 
there was no statistically significant difference between halop-
eridol and clozapine with regard to their propensity to induce
sexual dysfunction.(17)
Another  study  compared  sexual  dysfunction  in  male 
schizophrenics  on  clozapine  (N = 30)  with  those  on  other 
typical antipsychotics (N = 30) including depot preparation of 
haloperidol  and fluphenazine  and oral  perphenazine.  Rated 
on a sexual function questionnaire, significant difference was 
found in frequency of desire for sex, masturbatory erections 
and  number  of  orgasms  per  month,  inferring  that 
maintenance therapy with clozapine may be associated with a 
lesser  degree  of  sexual  dysfunction  than  the  typical 
antipsychotics.  The study was limited by only male patient 
population  and small  sample  size,  especially  in  the  typical 
antipsychotic group.(18)
Wirshing and associates also compared typical and atypical 
antipsychotics  for  sexual  dysfunction  in  25  male 
schizophrenic patients.  There were three groups,  clozapine 
(N = 5), risperidone (N = 14) and haloperidol / fluphenazine 
combination  (N  =  6).  Assessed  on  a  sexual  functioning 
questionnaire developed by Burke et al.(1994), the majority 
of  risperidone (71%) and haloperidol  /  fluphenazine (61%) 
treated subjects but less of clozapine (40%) treated subjects 
reported  overall  worsening of  sexual  functioning  including 
desire,  erection  and orgasm.  But  the small  and unbalanced 
number of subjects makes type II errors clearly possible and 
hampers  any  conclusions  about  legitimate  drug-  drug 
differences.(3)
In the Nithsdale Schizophrenia Survey 24, assessing sexual 
dysfunction among schizophrenic patients in comparison to 
healthy control  group,  at  least  one  sexual  dysfunction  was 
reported  by  82%  of  men  and  96%  of  women  with 
schizophrenia  on  a  gender  specific  questionnaire.  Among 
men, 52% each had desire and arousal difficulties and 35% 
had orgasmic  difficulties.  Seventy three percent of  females 
reported  reduced  desire  and  46%  orgasmic  difficulties. 
Patients  taking  typical  and  atypical  antipsychotics  were 
evenly matched.  Patients  on  both  groups  of  antipsychotics 
showed similar frequency of sexual dysfunction. There was 
no  association  between  sexual  dysfunction  and  type  of 
antipsychotic drug.(19)
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Bobes  and  colleagues  studied  cross-sectionally  sexual 
dysfunction  with  risperidone,  olanzapine,  quetiapine  and 
haloperidol  among 636 patients of  schizophrenia; assessing 
them on  UKU side  effect  rating  scale.  Patients  were  on  a 
single  antipsychotic.  Frequency  of  sexual  dysfunction  was 
38% with  haloperidol,  35.3% with  olanzepine,  43.2% with 
risperidone and 18.2% with quetiapine. None of the atypical 
antipsychotics  studied  significantly  improved  sexual 
dysfunction  due  to  typical  antipsychotics.  Lesser  sexual 
dysfunction  due  to  quetiapine  was  presumed  to  be  due  to 
short-term treatment.(20)
A recent randomized, double-blind, 12 week trial has studied 
27 patients of schizophrenia who were on fluphenazine(n=9), 
risperidone(n=12)  and  quetiapine(n=6)  for  sexual 
dysfunction. The patients were rated on ‘Changes in Sexual 
Function Questionnaire’. Seventy-eight percent of patients on 
fluphenazine  reported  sexual  dysfunction  as  compared  to 
42%  on  risperidone  and  50%  on  quetiapine.  However 
orgasmic quality/ability improved significantly for quetiapine 
as compared to other study drugs. Forty percent of quetiapine 
treated  patients  reported  that  they  felt  better  about  their 
sexuality as compared to previous treatment, as did 55% on 
risperidone  and  only  13%  on  fluphenazine.  Prolactin 
elevation  and  consequent  hormonal  problems  were  highest 
with risperidone.(21)
There  have  been  several  studies  as  sited  above  that  have 
compared either typical and atypical antipsychotics or several 
atypical  antipsychotics  with  a  typical  antipsychotic.  Many 
studies have shown that there is no statistical significance in 
the  occurrence  of  sexual  side  effects  among  typical  and 
atypical  antipsychotics.  However  in  general,  atypical 
antipsychotics have better short term side effect profile. Thus 
by  the  beginning  of  this  century,  usage  of  typical 
antipsychotics  was  much  reduced.  Though  most  of  the 
atypical  antipsychotics  are  associated  with  sexual 
dysfunction, it is important to know which is relatively safer 
among them, with respect to sexual side effects.
Studies  comparing  different  atypical  antipsychotics  for 
sexual dysfunction:
Knegtering  and  associates  studied  49  patients  of 
schizophrenia  and  other  psychotic  disorders  for  sexual 
dysfunction due to quetiapine (200-1200 mg/day) (n=25) and 
risperidone (1-6 mg/day) (n=24) in a randomized open label 
study. Assessed on a sexual functioning questionnaire, 16% 
of  those  on  quetiapine  reported  sexual  dysfunction  as 
compared to 50% on risperidone thus concluding that sexual 
dysfunction is significantly less common in quetiapine than 
risperidone. (22) This finding is supported by another study 
in  which  the  author  switched  schizophrenic  patients  on 
risperidone (n=7) and haloperidol (n=1) who had developed 
sexual dysfunction due to these agents, to quetiapine for six 
weeks  and  found  significant  improvement  both  in  sexual 
dysfunction, as assessed by Arizona Sexual Experience Scale 
as well as in psychotic symptoms as assessed on PANSS.(23)
Melkersson  studied  cross-sectionally  the  degree  and 
frequency  of  prolactin  elevation  and  related  symptoms  of 
menstrual  disturbances,  galactorrhea,  impotence  and 
decreased  libido  in  patients  with  schizophrenia, 
schizophreniform and schizoaffective  disorders  who are on 
clozapine (n=28), olanzapine (n=29) and risperidone (n=18). 
Elevated prolactin was found in 89% of those on risperidone, 
24%  of  those  on  olanzapine  and  none  among  those  on 
clozapine.  Further,  impotence  and  reduced  libido  were 
reported in 44% of risperidone treated patients as compared 
to 3% of olanzapine and none of clozapine treated patients. 
However  whether  the  severity  of  these  adverse  effects  is 
related to the extent of hyperprolactinemia was not studied 
here. Overall, clozapine was found to be the more favourable 
agent  when  compared  to  risperidone  and  olanzapine,  with 
respect to sexual functioning.(24)
Montejo  and  colleagues  studied  sexual  side  effects  of 
quetiapine  alone,  in  an open-label,  prospective,  naturalistic 
study having five assessments over six months. They rated 82 
patients  with  a  diagnosis  of  schizophrenia  or 
schizophreniform disorder,  on  quetiapine  in  a  real  practice 
setting,  on  ‘Psychotropic-Related  Sexual  Dysfunction 
Questionnaire’. Total scores on this questionnaire decreased 
progressively and significantly from baseline to the study end 
point.  The  authors  infer  that  quetiapine  shows  a  low 
frequency of sexual dysfunction during long-term treatment.
(25)
In contrast  to  the  above  mentioned  study,  Atmaca  and co-
workers  studied  quetiapine  alone  for  sexual  dysfunction. 
They evaluated 36 schizophrenic patients on quetiapine for 4 
weeks using Arizona Sexual Experience Scale and found that 
31.6% of males and 28.6% of  females had impaired libido 
which was not  there  at  baseline.  Thus they concluded that 
even quetiapine causes significant sexual dysfunction.(26)
Another recent study compared risperidone, olanzapine and 
quetiapine  for  sexual  dysfunction  using  the  same 
questionnaire, Arizona Sexual Experience Scale (ASEX). It 
was  a  cross-sectional  study  with  a  sample  size  of  238 
(quetiapine-57,  olanzapine-94,  risperidone-87).  The  mean 
scores  on  ASEX  were  relatively  low  in  quetiapine  group 
compared to the other two drugs. However patients in all the 
treatment  groups  experienced a  moderately  high  degree  of 
sexual  dysfunction.  Though  quetiapine  group  experienced 
slightly  lesser  degree  of  sexual  dysfunction,  it  differed 
significantly with olanzapine only. Because the patients were 
not randomized, the authors opine that conclusions must be 
interpreted  within  the  context  of  the  quasi-experimental 
design.(27)
In  a  unique,  six  week  study,  Knegtring  and  colleagues 
compared  prolactin  rising  and  prolactin  sparing 
antipsychotics for sexual dysfunction.  The objective was to 
study  whether  the  sexual  side  effects  of  prolactin  rising 
antipsychotics are reducible to serum prolactin. Around 40% 
of  emerging  sexual  side  effects  in  schizophrenia  were 
attributable  to  the  prolactin  rising  properties  of 
antipsychotics. Of this attributable fraction, around one-thirds 
to  two-thirds  was directly reducible  to the  effect of  serum 
prolactin.(28)
Antipsychotic  induced  hyperprolactinemia  and  sexual 
dysfunction:
The  prolactin  is  secreted  from  the  anterior  pituitary  in  a 
pulsatile  manner  and  is  regulated  by  inhibitory  and 
stimulatory influences from the hypothalamus. There are 13-
14 peaks per day with an interpulse interval of about 95 min. 
The primary influence is tonic inhibitory, and dopamine has a 
major  role  in  mediating this  inhibition.  Dopamine  released 
into  the  hypophysial  portal  blood  from  tuberoinfundibular 
neurons activates D2 receptors on lactotrophs in the anterior 
pituitary.(4) All antipsychotics are dopamine blockers, while 
some antipsychotics are also serotonin blockers. Blockade of 
dopamine  receptors  by  antipsychotics  in  the 
tuberoinfundibular  tract  releases  the  inhibition  of  prolactin 
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storage  cells,  resulting  in  elevation  of  prolactin  levels.  In 
contrast  to  dopamine,  serotonin  acts  to  stimulate  prolactin 
release, thus having an inhibiting effect on the dopaminergic 
influence on the tuberoinfundibular tract. A consequence of 
this mechanism is that serotonergic influences can modulate 
prolactin release, but serotonin can only show this effect as 
long  as  the  dopaminergic  influence  is  present.  Atypical 
antipsychotics  are  antagonists  of  both  serotonin  and 
dopamine, exerting opposing effects on prolactin release. The 
net effect would depend on the relative strength of the two 
actions. Thus risperidone causes greater degree of prolactin 
elevation, olanzapine has only marginal effect and quetiapine 
has no effect on prolactin elevation.(29)
Elevation  of  the  prolactin  level  can  have  different 
consequences  for  male  and  female  antipsychotic  users. 
Leutinising hormone (LH) stimulates testosterone production 
in men. If prolactin levels are rising, gonadotropin-releasing 
hormone (GnRH) levels and consequently LH levels will fall. 
This might result in a decrease of testosterone levels, which 
might contribute to sexual function disorders. These include 
loss  of  libido,  erectile  dysfunction,  and  difficulty  in 
ejaculating  or  an  ejaculation  without  orgasm,  though  the 
effects of prolactin on arousal and orgasm remain equivocal. 
In women, elevated prolactin levels can result in changes of 
pulse released GnRH and lack of estrogen, which can induce 
inhibition  of  menstrual  cycle  (amenorrhoea).  It  also causes 
galactorrhoea,  gynaecomastia  and  various  types  of  sexual 
dysfunction, especially loss of libido.(4,29)
A  number  of  studies  on  antipsychotic  induced  sexual 
dysfunction have incorporated the procedure of measurement 
of prolactin level. Almost all of them have found a positive 
correlation  between  hyperprolactinemia  and  sexual 
dysfunction.  (2,8,10,12,21,24,28,30)  When  it  comes  to  the 
proportion of cases where hyperprolactinemia was associated 
with sexual dysfunction, studies infer it to be 25-40%. (28, 
31) Thus it is not just hyperprolactinemia, and there are other 
mechanisms that are involved in sexual dysfunction. Studies 
have  revealed  significant  contribution  of  dopaminergic, 
adrenergic,  serotonergic  and  cholinergic  actions  of 
antipsychotics  for  sexual  dysfunction.  (7,8,32)  In  fact  a 
recent  study  has  reported  that  the  mostly  responsible 
mechanism of sexual dysfunction is the direct consequence of 
dopamine antagonism.(8)
Treatment options:
The robust evidence that we have today as a mechanism of 
sexual dysfunction is hyperprolactinema. Thus the principle 
behind treating antipsychotic  induced sexual dysfunction  is 
reducing prolactin levels. The reverting back of the prolactin 
levels to normal range has been found to set right the sexual 
dysfunction. The treatment protocol may involve a morning 
random  measurement  of  the  non-fasting  serum  prolactin 
level. Following are the various treatment options.(5, 9)
• Discontinuation of  the antipsychotic  if  clinically 
indicated
• Dose  reduction  of  conventional  antipsychotic  or 
risperidone
• Switching to clozapine, olanzapine or quetiapine
• Hormone replacement therapy
• Addition of drugs like dopaminergic agonists
The last of the above options is used where dose reduction 
has failed and switching is contra-indicated. The following 
are some of the drugs used to reduce prolactin levels.
Bromocriptine: It  is  an  ergot  alkaloid  derivative,  having 
dopamine agonist properties. It is the choice of treatment of 
hyperprolactinemia, irrespective of the etiology. It is given in 
daily  divided  doses  of  5-10  mg.  It  can  be  safely  used  in 
modest doses in patients taking conventional antipsychotics. 
It  is  found to  improve  the  libido,  normalize  the  menstrual 
cycle and increase the serum testosterone levels.(33,34)
Amantadine: It  also  acts  as  dopamine  agonist  and  is 
beneficial  in  the  treatment  of  antipsychotic  induced 
hyperprolactinemia. When used in the dose of 100 mg/day, it 
reverses the sexual dysfunction.(35)
Cabergoline: It is a synthetic ergoline, a selective and long-
lasting D2 receptor agonist that inhibits prolactin secretion. It 
is found to be effective at a dose of 0.5 mg twice a week. 
However  it  is  not  as  effective  as  the  other  two dopamine 
agonists.(36)
Sildenafil: Only three case reports and one open-label trial 
mentioned  the  use  of  sildenafil  in  antipsychotic  induced 
sexual dysfunction. (37-40) However, the limitation with its 
use is that it cannot be used on a regular basis for a long time 
due to cardiovascular adversities.
Shakuyaku-Kanzo-To (TJ-68): It  is  a  Japanese  medicine 
that  is  composed  of  two  herbs  (Radix  paeoniae  &  Radix 
glycyrrhizae) that are used to treat menstrual pains. Although 
the  mechanism  is  unknown,  TJ-68  may  have  a  direct 
inhibitory effect on prolactin release from pituitary.  It  also 
may have an indirect effect by reducing estradiol.(41,42)
These  pharmacological  strategies  described  above,  once 
initiated, should not be discontinued until a minimum of two 
weeks  of  therapy  have  been  administered.  One  can  also 
combine  certain  non-pharmacological  therapies  along  with 
the  medication.  The  most  important  among  them  is  a 
thorough psychoeducation about the course and prognosis of 
psychotropic associated sexual dysfunction, as many patients 
are of the opinion that this sexual dysfunction is everlasting. 
Drug  holiday  (43)  and  watchful  waiting  for  sexual  side 
effects to disappear (44) are other useful methods.
Conclusion:
Sexual dysfunction is an important antipsychotic associated 
side effect. All patients on follow up need an evaluation for 
sexual dysfunction. Hyperprolactinemia is a neuroendocrine 
side  effect  of  conventional  antipsychotics  and  risperidone, 
and is a likely cause of sexual disturbances in patients taking 
antipsychotics. Successful management of sexual side effects 
is very crucial for treatment adherence to antipsychotics. The 
existing studies  have  rarely used procedures like  nocturnal 
penile tumescence or penile plethysmography, which can rule 
out  any  organic  sexual  disorder.  Such  methodological 
shortcomings should be overcome in future studies. Further, 
much  research  is  required  in  the  area  of  treatment  of 
antipsychotic induced sexual dysfunction 
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